



12 February 2024

cyclo**medica**
techne**gas**

The Manager
Company Announcements Office
Australian Securities Exchange Limited
20 Bridge Street
Sydney NSW 2000

Cyclopharm Ltd
ABN 74 116 931 250
Unit 4, 1 The Crescent
Kingsgrove NSW 2208 Australia
T 61 2 9541 0411
F 61 2 9543 0960
www.cyclopharm.com.au

CYCLOPHARM APPOINTS JASON SMITH AS CFO

Cyclopharm Limited (ASX: CYC) is pleased to announce the appointment of Mr. Jason Smith as Chief Financial Officer (CFO), effective 26 February 2024.

Mr. Smith brings a wealth of industry experience, having held several senior finance roles at Cochlear Ltd (ASX: COH) over the past 15 years. For the last 7 years, he has served as the Director Financial Planning & Analysis - Asia Pacific, overseeing global and regional responsibilities. In this role, he demonstrated leadership in forecasting, strategic alignment, and driving commercial understanding and insights across China, ANZ, Japan, Korea, India, and South-East Asia.

Prior to his current role, Mr. Smith held positions in Financial Control and Accounting, both at Cochlear and at a large multinational in the United Kingdom. He is CA qualified, gained through his time working as an external auditor at Deloitte, and holds an MBA.

Mr. Smith's diverse finance experience and commercial acumen within the healthcare industry will undoubtedly strengthen the Cyclopharm team.

Managing Director & Chief Executive Officer, Mr. James McBrayer, commented: "We are thrilled to welcome Jason to Cyclopharm as our new Chief Financial Officer. His extensive experience in senior finance roles, particularly his leadership in financial planning and analysis in the Asia Pacific region, will be invaluable to our company. The recent United States Food and Drug Administration approval for Technegas marks a pivotal moment for Cyclopharm, opening doors to substantial growth. Jason's proven track record and strategic insights within the healthcare industry aligns very well with our goals. We are confident that his contributions will further enhance our financial capabilities and drive the company's success. We look forward to a prosperous future with Jason on board."

The Board and management of Cyclopharm extend their warmest congratulations to Mr. Jason Smith on his appointment and eagerly anticipate the positive impact he will bring to the company

- ENDS -

This ASX announcement was approved and authorised for release by James McBrayer, Managing Director, CEO and Company Secretary.

For more information, please contact:

Mr James McBrayer
Managing Director, CEO and Company Secretary
Cyclopharm Limited
T: +61 (02) 9541 0411

Cyclopharm Limited

Cyclopharm is an ASX Listed radiopharmaceutical company servicing the global medical community. The Company's mission is to provide nuclear medicine and other clinicians with the ability to improve patient care outcomes. Cyclopharm achieves this objective primarily through the provision of its core radiopharmaceutical product, Technegas® used in functional lung ventilation imaging.

Technegas®

The Technegas® technology is a structured ultra-fine dispersion of radioactive labelled carbon, produced by using dried Technetium-99m in a carbon crucible, micro furnaced for a few seconds at around 2,700° C. The resultant gas like substance is inhaled by the patient (lung ventilation) via a breathing apparatus, which then allows multiple views and tomography imaging under a gamma or single photon emission computed tomography (SPECT) camera for evaluating functional ventilation imaging. Historically used in the diagnosis of pulmonary embolism, Technegas®, together with advancements in complementary technology to multimodality imaging and analytical software, is being used in other disease states to include COPD, asthma, pulmonary hypertension, Long COVID and certain interventional applications to include lobectomies in lung cancer and lung volume reduction surgery.